Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney
HALIMI, Jean-Michel; Pantelis SARAFIDIS; Michel AZIZI; Grzegorz BILO; Thilo BURKARD et al.
Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney
Autoři
HALIMI, Jean-Michel; Pantelis SARAFIDIS; Michel AZIZI; Grzegorz BILO; Thilo BURKARD; Michael BURSZTYN; Miguel CAMAFORT; Neil CHAPMAN; Santina COTTONE; de Backer TINE; Jaap DEINUM; Philippe DELMOTTE; Maria DOROBANTU; Michalis DOUMAS; Rainer DUSING; Beatrice DULY-BOUHANICK; Jean-Pierre FAUVEL; Pierre FESLER; Zbigniew GACIONG; Eugenia GKALIAGKOUSI; Daniel GORDIN; Guido GRASSI; Charalampos GRASSOS; Dominique GUERROT; Justine HUART; Raffaele IZZO; Fernando Jaen AGUILA; Zoltan JARAI; Thomas KAHAN; Ilkka KANTOLA; Eva KOCIANOVA; FlorianP LIMBOURG; Marilucy LOPEZ-SUBLET; Francesca MALLAMACI; Athanasios MANOLIS; Maria MARKETOU; Gert MAYER; Alberto MAZZA; IainM MACINTYRE; Jean-Jacques MOURAD; Maria Lorenza MUIESAN; Edgar NASR; Peter NILSSON; Anna OLIVERAS; Olivier ORMEZZANO; Vitor PAIXAO-DIAS; Ioannis PAPADAKIS; Dimitris PAPADOPOULOS; Sabine PERL; Jorge POLONIA; Roberto PONTREMOLI; Giacomo PUCCI; Nicolas Roberto ROBLES; Sebastien RUBIN; Luis Miguel RUILOPE; Lars Christian RUMP; Sahrai SAEED; Elias SANIDAS; Riccardo SARZANI; Roland SCHMIEDER; Francois SILHOL; Sekib SOKOLOVIC; Marit SOLBU; Miroslav SOUČEK; George STERGIOU; Isabella SUDANO; Ramzi TABBALAT; Istemihan TENGIZ; Helen TRIANTAFYLLIDI; Konstontinos TSIOUFIS; Jan VACLAVIK; van der Giet MARKUS; Van der Niepen PATRICIA; Franco VEGLIO; RetoM VENZIN; Margus VIIGIMAA; Thomas WEBER; Jiri WIDIMSKY; Gregoire WUERZNER; Parounak ZELVEIAN; Pantelis ZEBEKAKIS; Stephan LUEDERS; Alexandre PERSU; Reinhold KREUTZ a Liffert VOGT
Vydání
Blood Pressure, Oxon, TAYLOR & FRANCIS, 2024, 0803-7051
Objective Real-life management of patients with hypertension and chronic kidney disease (CKD) among European Society of Hypertension Excellence Centres (ESH-ECs) is unclear : we aimed to investigate it. Methods A survey was conducted in 2023. The questionnaire contained 64 questions asking ESH-ECs representatives to estimate how patients with CKD are managed. Results Overall, 88 ESH-ECS representatives from 27 countries participated. According to the responders, renin-angiotensin system (RAS) blockers, calcium-channel blockers and thiazides were often added when these medications were lacking in CKD patients, but physicians were more prone to initiate RAS blockers (90% [interquartile range: 70-95%]) than MRA (20% [10-30%]), SGLT2i (30% [20-50%]) or (GLP1-RA (10% [5-15%]). Despite treatment optimisation, 30% of responders indicated that hypertension remained uncontrolled (30% (15-40%) vs 18% [10%-25%]) in CKD and CKD patients, respectively). Hyperkalemia was the most frequent barrier to initiate RAS blockers, and dosage reduction was considered in 45% of responders when kalaemia was 5.5-5.9 mmol/L. Conclusions RAS blockers are initiated in most ESH-ECS in CKD patients, but MRA and SGLT2i initiations are less frequent. Hyperkalemia was the main barrier for initiation or adequate dosing of RAS blockade, and RAS blockers' dosage reduction was the usual management.
HALIMI, Jean-Michel; Pantelis SARAFIDIS; Michel AZIZI; Grzegorz BILO; Thilo BURKARD; Michael BURSZTYN; Miguel CAMAFORT; Neil CHAPMAN; Santina COTTONE; de Backer TINE; Jaap DEINUM; Philippe DELMOTTE; Maria DOROBANTU; Michalis DOUMAS; Rainer DUSING; Beatrice DULY-BOUHANICK; Jean-Pierre FAUVEL; Pierre FESLER; Zbigniew GACIONG; Eugenia GKALIAGKOUSI; Daniel GORDIN; Guido GRASSI; Charalampos GRASSOS; Dominique GUERROT; Justine HUART; Raffaele IZZO; Fernando Jaen AGUILA; Zoltan JARAI; Thomas KAHAN; Ilkka KANTOLA; Eva KOCIANOVA; FlorianP LIMBOURG; Marilucy LOPEZ-SUBLET; Francesca MALLAMACI; Athanasios MANOLIS; Maria MARKETOU; Gert MAYER; Alberto MAZZA; IainM MACINTYRE; Jean-Jacques MOURAD; Maria Lorenza MUIESAN; Edgar NASR; Peter NILSSON; Anna OLIVERAS; Olivier ORMEZZANO; Vitor PAIXAO-DIAS; Ioannis PAPADAKIS; Dimitris PAPADOPOULOS; Sabine PERL; Jorge POLONIA; Roberto PONTREMOLI; Giacomo PUCCI; Nicolas Roberto ROBLES; Sebastien RUBIN; Luis Miguel RUILOPE; Lars Christian RUMP; Sahrai SAEED; Elias SANIDAS; Riccardo SARZANI; Roland SCHMIEDER; Francois SILHOL; Sekib SOKOLOVIC; Marit SOLBU; Miroslav SOUČEK; George STERGIOU; Isabella SUDANO; Ramzi TABBALAT; Istemihan TENGIZ; Helen TRIANTAFYLLIDI; Konstontinos TSIOUFIS; Jan VACLAVIK; van der Giet MARKUS; Van der Niepen PATRICIA; Franco VEGLIO; RetoM VENZIN; Margus VIIGIMAA; Thomas WEBER; Jiri WIDIMSKY; Gregoire WUERZNER; Parounak ZELVEIAN; Pantelis ZEBEKAKIS; Stephan LUEDERS; Alexandre PERSU; Reinhold KREUTZ a Liffert VOGT. Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney. Blood Pressure. Oxon: TAYLOR & FRANCIS, 2024, roč. 33, č. 1, s. 1-10. ISSN 0803-7051. Dostupné z: https://doi.org/10.1080/08037051.2024.2368800.
@article{2486937, author = {Halimi, JeanandMichel and Sarafidis, Pantelis and Azizi, Michel and Bilo, Grzegorz and Burkard, Thilo and Bursztyn, Michael and Camafort, Miguel and Chapman, Neil and Cottone, Santina and Tine, de Backer and Deinum, Jaap and Delmotte, Philippe and Dorobantu, Maria and Doumas, Michalis and Dusing, Rainer and DulyandBouhanick, Beatrice and Fauvel, JeanandPierre and Fesler, Pierre and Gaciong, Zbigniew and Gkaliagkousi, Eugenia and Gordin, Daniel and Grassi, Guido and Grassos, Charalampos and Guerrot, Dominique and Huart, Justine and Izzo, Raffaele and Aguila, Fernando Jaen and Jarai, Zoltan and Kahan, Thomas and Kantola, Ilkka and Kocianova, Eva and Limbourg, FlorianP and LopezandSublet, Marilucy and Mallamaci, Francesca and Manolis, Athanasios and Marketou, Maria and Mayer, Gert and Mazza, Alberto and MacIntyre, IainM and Mourad, JeanandJacques and Muiesan, Maria Lorenza and Nasr, Edgar and Nilsson, Peter and Oliveras, Anna and Ormezzano, Olivier and PaixaoandDias, Vitor and Papadakis, Ioannis and Papadopoulos, Dimitris and Perl, Sabine and Polonia, Jorge and Pontremoli, Roberto and Pucci, Giacomo and Robles, Nicolas Roberto and Rubin, Sebastien and Ruilope, Luis Miguel and Rump, Lars Christian and Saeed, Sahrai and Sanidas, Elias and Sarzani, Riccardo and Schmieder, Roland and Silhol, Francois and Sokolovic, Sekib and Solbu, Marit and Souček, Miroslav and Stergiou, George and Sudano, Isabella and Tabbalat, Ramzi and Tengiz, Istemihan and Triantafyllidi, Helen and Tsioufis, Konstontinos and Vaclavik, Jan and Markus, van der Giet and Patricia, Van der Niepen and Veglio, Franco and Venzin, RetoM and Viigimaa, Margus and Weber, Thomas and Widimsky, Jiri and Wuerzner, Gregoire and Zelveian, Parounak and Zebekakis, Pantelis and Lueders, Stephan and Persu, Alexandre and Kreutz, Reinhold and Vogt, Liffert}, article_location = {Oxon}, article_number = {1}, doi = {https://doi.org/10.1080/08037051.2024.2368800}, keywords = {Chronic kidney disease; hypertension; management; RAS blockers; hyperkalaemia; SGLT2 inhibitors; mineralocorticoid receptor antagonists; guidelines}, language = {eng}, issn = {0803-7051}, journal = {Blood Pressure}, title = {Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney}, url = {https://www.tandfonline.com/doi/full/10.1080/08037051.2024.2368800}, volume = {33}, year = {2024} }
TY - JOUR ID - 2486937 AU - Halimi, Jean-Michel - Sarafidis, Pantelis - Azizi, Michel - Bilo, Grzegorz - Burkard, Thilo - Bursztyn, Michael - Camafort, Miguel - Chapman, Neil - Cottone, Santina - Tine, de Backer - Deinum, Jaap - Delmotte, Philippe - Dorobantu, Maria - Doumas, Michalis - Dusing, Rainer - Duly-Bouhanick, Beatrice - Fauvel, Jean-Pierre - Fesler, Pierre - Gaciong, Zbigniew - Gkaliagkousi, Eugenia - Gordin, Daniel - Grassi, Guido - Grassos, Charalampos - Guerrot, Dominique - Huart, Justine - Izzo, Raffaele - Aguila, Fernando Jaen - Jarai, Zoltan - Kahan, Thomas - Kantola, Ilkka - Kocianova, Eva - Limbourg, FlorianP - Lopez-Sublet, Marilucy - Mallamaci, Francesca - Manolis, Athanasios - Marketou, Maria - Mayer, Gert - Mazza, Alberto - MacIntyre, IainM - Mourad, Jean-Jacques - Muiesan, Maria Lorenza - Nasr, Edgar - Nilsson, Peter - Oliveras, Anna - Ormezzano, Olivier - Paixao-Dias, Vitor - Papadakis, Ioannis - Papadopoulos, Dimitris - Perl, Sabine - Polonia, Jorge - Pontremoli, Roberto - Pucci, Giacomo - Robles, Nicolas Roberto - Rubin, Sebastien - Ruilope, Luis Miguel - Rump, Lars Christian - Saeed, Sahrai - Sanidas, Elias - Sarzani, Riccardo - Schmieder, Roland - Silhol, Francois - Sokolovic, Sekib - Solbu, Marit - Souček, Miroslav - Stergiou, George - Sudano, Isabella - Tabbalat, Ramzi - Tengiz, Istemihan - Triantafyllidi, Helen - Tsioufis, Konstontinos - Vaclavik, Jan - Markus, van der Giet - Patricia, Van der Niepen - Veglio, Franco - Venzin, RetoM - Viigimaa, Margus - Weber, Thomas - Widimsky, Jiri - Wuerzner, Gregoire - Zelveian, Parounak - Zebekakis, Pantelis - Lueders, Stephan - Persu, Alexandre - Kreutz, Reinhold - Vogt, Liffert PY - 2024 TI - Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney JF - Blood Pressure VL - 33 IS - 1 SP - 1-10 EP - 1-10 PB - TAYLOR & FRANCIS SN - 08037051 KW - Chronic kidney disease KW - hypertension KW - management KW - RAS blockers KW - hyperkalaemia KW - SGLT2 inhibitors KW - mineralocorticoid receptor antagonists KW - guidelines UR - https://www.tandfonline.com/doi/full/10.1080/08037051.2024.2368800 N2 - Objective Real-life management of patients with hypertension and chronic kidney disease (CKD) among European Society of Hypertension Excellence Centres (ESH-ECs) is unclear : we aimed to investigate it. Methods A survey was conducted in 2023. The questionnaire contained 64 questions asking ESH-ECs representatives to estimate how patients with CKD are managed. Results Overall, 88 ESH-ECS representatives from 27 countries participated. According to the responders, renin-angiotensin system (RAS) blockers, calcium-channel blockers and thiazides were often added when these medications were lacking in CKD patients, but physicians were more prone to initiate RAS blockers (90% [interquartile range: 70-95%]) than MRA (20% [10-30%]), SGLT2i (30% [20-50%]) or (GLP1-RA (10% [5-15%]). Despite treatment optimisation, 30% of responders indicated that hypertension remained uncontrolled (30% (15-40%) vs 18% [10%-25%]) in CKD and CKD patients, respectively). Hyperkalemia was the most frequent barrier to initiate RAS blockers, and dosage reduction was considered in 45% of responders when kalaemia was 5.5-5.9 mmol/L. Conclusions RAS blockers are initiated in most ESH-ECS in CKD patients, but MRA and SGLT2i initiations are less frequent. Hyperkalemia was the main barrier for initiation or adequate dosing of RAS blockade, and RAS blockers' dosage reduction was the usual management. ER -
HALIMI, Jean-Michel; Pantelis SARAFIDIS; Michel AZIZI; Grzegorz BILO; Thilo BURKARD; Michael BURSZTYN; Miguel CAMAFORT; Neil CHAPMAN; Santina COTTONE; de Backer TINE; Jaap DEINUM; Philippe DELMOTTE; Maria DOROBANTU; Michalis DOUMAS; Rainer DUSING; Beatrice DULY-BOUHANICK; Jean-Pierre FAUVEL; Pierre FESLER; Zbigniew GACIONG; Eugenia GKALIAGKOUSI; Daniel GORDIN; Guido GRASSI; Charalampos GRASSOS; Dominique GUERROT; Justine HUART; Raffaele IZZO; Fernando Jaen AGUILA; Zoltan JARAI; Thomas KAHAN; Ilkka KANTOLA; Eva KOCIANOVA; FlorianP LIMBOURG; Marilucy LOPEZ-SUBLET; Francesca MALLAMACI; Athanasios MANOLIS; Maria MARKETOU; Gert MAYER; Alberto MAZZA; IainM MACINTYRE; Jean-Jacques MOURAD; Maria Lorenza MUIESAN; Edgar NASR; Peter NILSSON; Anna OLIVERAS; Olivier ORMEZZANO; Vitor PAIXAO-DIAS; Ioannis PAPADAKIS; Dimitris PAPADOPOULOS; Sabine PERL; Jorge POLONIA; Roberto PONTREMOLI; Giacomo PUCCI; Nicolas Roberto ROBLES; Sebastien RUBIN; Luis Miguel RUILOPE; Lars Christian RUMP; Sahrai SAEED; Elias SANIDAS; Riccardo SARZANI; Roland SCHMIEDER; Francois SILHOL; Sekib SOKOLOVIC; Marit SOLBU; Miroslav SOUČEK; George STERGIOU; Isabella SUDANO; Ramzi TABBALAT; Istemihan TENGIZ; Helen TRIANTAFYLLIDI; Konstontinos TSIOUFIS; Jan VACLAVIK; van der Giet MARKUS; Van der Niepen PATRICIA; Franco VEGLIO; RetoM VENZIN; Margus VIIGIMAA; Thomas WEBER; Jiri WIDIMSKY; Gregoire WUERZNER; Parounak ZELVEIAN; Pantelis ZEBEKAKIS; Stephan LUEDERS; Alexandre PERSU; Reinhold KREUTZ a Liffert VOGT. Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney. \textit{Blood Pressure}. Oxon: TAYLOR \&{} FRANCIS, 2024, roč.~33, č.~1, s.~1-10. ISSN~0803-7051. Dostupné z: https://doi.org/10.1080/08037051.2024.2368800.